Clinical Trial Update: Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder [Phase 1]

View source ↗

Summary

A Phase 1 study in COPD patients evaluated safety, tolerability, and pharmacokinetics after single inhaled doses of ciprofloxacin (50 mg and 75 mg).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Ciprofloxacin inhalation powder (ciprofloxacin)

Snippet

Sponsor: Bayer | Conditions: Infection, Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED